Latest Information Update: 22 Dec 1999
At a glance
- Originator Apollo BioPharmaceutics
- Class Neuroprotectants
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 22 Dec 1999 Discontinued-Preclinical for Stroke in USA (Unknown route)
- 07 Nov 1997 Preclinical development for Stroke in USA (Unknown route)